|Bid||277.15 x 100|
|Ask||283.00 x 100|
|Day's Range||277.64 - 282.89|
|52 Week Range||225.68 - 333.65|
|PE Ratio (TTM)||17.53|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for ...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Biogen, Inc. a score of 84. Our analysis is based on comparing Biogen, Inc. with the following peers – Amgen Inc., Celgene Corporation, Gilead Sciences, Inc., Johnson & Johnson, AbbVie, Inc., Pfizer Inc., Sanofi Sponsored ADR, Acorda Therapeutics, Inc., Sangamo Therapeutics, Inc. and Bio-Rad Laboratories, Inc. Class ... Read more (Read more...)
Nasdaq 100 futures edged higher Thursday morning as Oracle surged on strong earnings. On Wednesday, Celgene broke out as biotechs and business software increasingly lead the market rally.